As a natural scaffold material with bioactive and biodegradable properties, fibrin demonstrates multidimensional therapeutic advantages in periorbital rejuvenation, including biocompatibility, degradability, and growth factor release kinetics.This article systematically reviews the classification of fibrin and its characteristic differences, with a focus on elucidating its mechanisms of action in periorbital applications, such as structural support and immediate volume filling, biostimulation and tissue regeneration, and immunomodulation of the microenvironment.Significant progress has been made in current clinical techniques regarding fibrin sources and preparation, combination strategies, and efficacy evaluation.Current clinical evidence indicated that fibrin-based monotherapy or combination therapies can significantly improve periorbital fine lines, skin texture, and hollowing, technical challenges remain, including short duration of effect, insufficient mechanical support, and technique-sensitive injection protocols.Further research should focus on material modification and intelligent delivery systems to address these challenges, thereby providing breakthrough solutions for periorbital rejuvenation from transient improvement to long-term regeneration.

As a natural scaffold material with bioactive and biodegradable properties, fibrin demonstrates multidimensional therapeutic advantages in periorbital rejuvenation, including biocompatibility, degradability, and growth factor release kinetics.This article systematically reviews the classification of fibrin and its characteristic differences, with a focus on elucidating its mechanisms of action in periorbital applications, such as structural support and immediate volume filling, biostimulation and tissue regeneration, and immunomodulation of the microenvironment.Significant progress has been made in current clinical techniques regarding fibrin sources and preparation, combination strategies, and efficacy evaluation.Current clinical evidence indicated that fibrin-based monotherapy or combination therapies can significantly improve periorbital fine lines, skin texture, and hollowing, technical challenges remain, including short duration of effect, insufficient mechanical support, and technique-sensitive injection protocols.Further research should focus on material modification and intelligent delivery systems to address these challenges, thereby providing breakthrough solutions for periorbital rejuvenation from transient improvement to long-term regeneration.

Diabetic retinopathy(DR)is a common microvascular complication of diabetes and the leading cause of blindness among working-age adults globally,posing a significant public health challenge.The 2024 Diabetic Retinopathy Preferred Practice Pattern(PPP)released by the American Academy of Ophthalmology is the authoritative guideline in this field.Building on previous editions,the latest version provides comprehensive refinements,including optimized screening protocols,strengthened multifactorial risk factor management,revised disease staging criteria,and the integration of preci-sion-based treatment strategies,aiming to enhance the quality of DR management.This article offers a detailed interpreta-tion of the PPP 2024,in an attempt to serve as a key reference for ophthalmologists in diagnostic and therapeutic decision-making.

Diabetic retinopathy(DR)is a common microvascular complication of diabetes and the leading cause of blindness among working-age adults globally,posing a significant public health challenge.The 2024 Diabetic Retinopathy Preferred Practice Pattern(PPP)released by the American Academy of Ophthalmology is the authoritative guideline in this field.Building on previous editions,the latest version provides comprehensive refinements,including optimized screening protocols,strengthened multifactorial risk factor management,revised disease staging criteria,and the integration of preci-sion-based treatment strategies,aiming to enhance the quality of DR management.This article offers a detailed interpreta-tion of the PPP 2024,in an attempt to serve as a key reference for ophthalmologists in diagnostic and therapeutic decision-making.

Objective To develop a solid-phase red cell adherence(SPRC A)reagent kit for unexpected alloantibody i-dentification.Methods A solid-phase carrier for bounding red blood cell(RBC)was prepared by coating microstrip with succinimide,then panel cell suspensions were dispensed to microwells to produce RBC monolayers,after that,1×PBS(pH7.40)was used to lysis the RBC monolayer to form stroma monolayer.Prior to the drying procedure,drying medium suspension was added to microwell to protect stroma monolayer.The solid-phase microplate was successfully produced after the stroma had been dried in refrigerator at 4℃.IgG anti-E and anti-Fya with low titer were tested every two months with the reagent kit to observe its stability.Seventy-two plasma samples containing unexpected antibodies and 152 normal plasma samples were determined with SPRCA reagent kit and column agglutination technique(CAT).Performances including sensi-tivity and specificity of the two reagents were compared by paired chi-square test.Results RBC stroma monolayer could be attached well on microwell bottom coated with succinimide.Drying medium suspension could provide effective protection for stroma monolayer.Both IgG anti-E and anti-Fya with low titer were determined well by the reagent kit during the storage peri-od.Of the 72 positive samples,70 were identified correctly by SPRCA kit and 71 by CAT[Sensitivity:97.22％(70/72)vs 98.61％(71/72)].Of the 152 negative plasma samples,149 were correctly detected by SPRCA kit and 152 by CAT[Spe-cificity:98.02％(149/152)vs 100％(152/152)].Paired chi-square test showed no significant differences between the two reagents(P＞0.05).Conclusion A SPRCA reagent kit for IgG unexpected antibody identification had been developed suc-cessfully.

Obsessive-compulsive disorder (OCD) is a disabling mental disorder with unclear etiology. The association between OCD occurrence and development and gut microbiota has not been fully elucidated. Although the exact pathogenic mechanism of OCD remains obscure, existing evidence indicates that the brain-gut axis is involved in OCD via multiple pathways, including immune inflammation, neurotransmitters, and endocrinology. This article reviews new evidence on the role of microbiota in OCD pathophysiology and their potential as a novel treatment. It summarizes current research methods and limitations regarding the brain-gut axis. We discuss the potential and challenges of microbial reconditioning strategies such as probiotics and fecal microbiota transplantation for OCD treatment and envision future research directions. The perspective in-depth study of the brain-gut axis may provide new therapeutic targets and perspectives for OCD.

Obsessive-compulsive disorder (OCD) is a disabling mental disorder with unclear etiology. The association between OCD occurrence and development and gut microbiota has not been fully elucidated. Although the exact pathogenic mechanism of OCD remains obscure, existing evidence indicates that the brain-gut axis is involved in OCD via multiple pathways, including immune inflammation, neurotransmitters, and endocrinology. This article reviews new evidence on the role of microbiota in OCD pathophysiology and their potential as a novel treatment. It summarizes current research methods and limitations regarding the brain-gut axis. We discuss the potential and challenges of microbial reconditioning strategies such as probiotics and fecal microbiota transplantation for OCD treatment and envision future research directions. The perspective in-depth study of the brain-gut axis may provide new therapeutic targets and perspectives for OCD.

Nanotechnology has emerged as an ideal approach for achieving the efficient chemo agent delivery. However, the potential toxicity and unclear internal metabolism of most nano-carriers was still a major obstacle for the clinical application. Herein, a novel "core‒shell" co-assembly carrier-free nanosystem was constructed based on natural sources of ursolic acid (UA) and polyphenol (EGCG) with the EpCAM-aptamer modification for hepatocellular carcinoma (HCC) synergistic treatment. As the nature products derived from food-plant, UA and EGCG had good anticancer activities and low toxicity. With the simple and "green" method, the nanodrugs had the advantages of good stability, pH-responsive and strong penetration of tumor tissues, which was expected to increase tumor cellular uptake, long circulation and effectively avoid the potential defects of traditional carriers. The nanocomplex exhibited the low cytotoxicity in the normal cells

【Objective】 To find the HLA-matched platelets from platelet donor registry and track the transfusion effect for aplastic anemia patients in pregnancy with platelet transfusion refractory (PTR) caused by anti-HLA, so as to support the childbirth and follow-up treatment of the patients. 【Methods】 Antibodies to HPA and HLA were detected by ELISA kit and Luminex, respectively. DNA of the patient and 523 platelet donors from the donor registry were extracted for high-resolution HLA genotyping. The Risk Factors Evaluation Software of PTR was used to select the ABO-compatible and HLA-matched donors, without HLA Eplets specific to the patient. After MASPAT cross matching, the patient was transfused with 1 U of platelets, and the 24h post-transfusion effect was recorded. 【Results】 Only anti-HLAⅠantibody was found in the patient serum, and the specificity Eplet was 65QIA, including HLA-B^*27∶08, B^*27∶05, B^*07∶02, B^*55∶01, B^*67∶01 and B^*54∶01; anti-HLA Ⅱ antibody was negative. The HLA genotypes of both the patient and donor were HLA-A^*02∶07, A^*11∶01, B^*46∶01, B^*46∶01, C^*01∶02, 01∶03, DRB1^*04∶05, DRB1^*0901, DQB1^*03∶03 and DQB1^*04∶01. The results of MASPAT matching were negative. HLA-matched platelets transfusion provided a satisfactory posttransfusion platelet responses in patients(1 before vs 33 ×10⁹/L after). A baby boy was delivered by cesarean section 4 weeks later, and the same donor was recruited due to the mother′s low Plt and bleeding trend. The 24h posttransfusion Plt (×10⁹ / L) rose from 5 to 37 after the secondary transfusion of 1U platelet. The vital signs of the mother and her baby were normal during the two-day follow up. 【Conclusion】 The establishment of blood donor registry and screening of HLA-matched donors is an effective approach to treat PTR caused by HLA antibodies in pregnancy complicated with aplastic anemia.

OBJECTIVE: To construct eukaryotic expression vectors for human platelet CD36 gene 220 C>T and 429+4insg variants and analyze their expressions in HEK293T cells. METHODS: RNA was isolated from human platelets and reversely transcribed into cDNA. Sequences of 220C>T and 429+4insg variants were derived by PCR amplification. The target sequence was ligated into a pcDNA3.1/V5-His-TOPO vector by TA cloning, which was transformed into TOP10 E. coli. Positive plasmids were screened by blue-white selection. After sequencing, plasmid DNA carrying 220C>T or 429+4insg variant was used to transfect HEK293T cells with the help of effectene. Expression of CD36 protein was then analyzed by flow cytometry and Western blotting. RESULTS: An eukaryotic expression vector pcDNA3.1/V5-His-CD36 (220C>T/429+4insg) was constructed by TA cloning. After transfected into HEK293T cells, the 220C>T and 429+4insg variants resulted in CD36 deficiency in HEK cells, which was confirmed by flow cytometry and Western blotting. CONCLUSION The 220C>T and 429+4insg variants can cause CD36 deficiency in human platelets. This system may be used for assessing the effect of 220C>T, 429+4insg, and other variants on the expression of CD36.
Blood Platelets ; CD36 Antigens ; Cloning, Molecular ; Escherichia coli ; Eukaryota ; Genetic Vectors ; HEK293 Cells ; Humans ; Plasmids ; Transfection